A retrospective study revealed that RB1 and TP53 were the most prevalent mutations in patients with EGFR‐mutant NSCLC converting to SCLC, accounting for 68% and 36% of cases, respectively.127. Here, EGFR is linked to non-small cell lung carcinoma.